JP2020191872A - Agents for improving exogenous gene transfer efficiency to mammalian cells - Google Patents
Agents for improving exogenous gene transfer efficiency to mammalian cells Download PDFInfo
- Publication number
- JP2020191872A JP2020191872A JP2020105583A JP2020105583A JP2020191872A JP 2020191872 A JP2020191872 A JP 2020191872A JP 2020105583 A JP2020105583 A JP 2020105583A JP 2020105583 A JP2020105583 A JP 2020105583A JP 2020191872 A JP2020191872 A JP 2020191872A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- foreign gene
- inhibits
- kinase activity
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 74
- 210000004962 mammalian cell Anatomy 0.000 title claims abstract description 30
- 238000012546 transfer Methods 0.000 title claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 98
- 230000000694 effects Effects 0.000 claims abstract description 43
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 32
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 32
- 239000012528 membrane Substances 0.000 claims abstract description 32
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 108091006146 Channels Proteins 0.000 claims abstract description 9
- 150000001768 cations Chemical class 0.000 claims abstract description 9
- 230000035699 permeability Effects 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 24
- 210000004899 c-terminal region Anatomy 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 11
- 241000702421 Dependoparvovirus Species 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000002207 retinal effect Effects 0.000 claims description 7
- 102000001301 EGF receptor Human genes 0.000 claims description 5
- 108060006698 EGF receptor Proteins 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 abstract description 5
- 230000004382 visual function Effects 0.000 abstract description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract description 3
- 230000008472 epithelial growth Effects 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 28
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 28
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 28
- 239000013607 AAV vector Substances 0.000 description 25
- 239000000126 substance Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 6
- 238000012404 In vitro experiment Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 108010035848 Channelrhodopsins Proteins 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000000857 visual cortex Anatomy 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 101000756400 Human T-cell leukemia virus 2 Protein Rex Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 241000195615 Volvox Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Abstract
Description
本発明は、哺乳動物細胞に対する外来遺伝子の導入効率の向上剤に関する。 The present invention relates to an agent for improving the efficiency of introducing a foreign gene into mammalian cells.
哺乳動物細胞に対して外来遺伝子を導入する方法には様々な方法が存在するが、その一つとしてウイルスベクターを利用する方法が知られている。この方法は、ゲノムに目的遺伝子を組み込んだウイルスを標的細胞に感染させることによって、目的遺伝子を標的細胞に送り込むものであり、ウイルスベクターのなかでもアデノ随伴ウイルス（ａｄｅｎｏ−ａｓｓｏｃｉａｔｅｄ ｖｉｒｕｓ：以下「ＡＡＶ」と略称する）ベクターは、ヒトに対する安全性が高いウイルスベクターとして、すでに遺伝子治療において実用化されている。しかしながら、ＡＡＶの哺乳動物細胞への感染効率は、細胞の種類や由来によって様々であることから、感染効率が低い細胞が標的細胞である場合、標的細胞に対する目的遺伝子の導入効率が劣ることで、充分な遺伝子治療の効果が発揮されない。 There are various methods for introducing a foreign gene into mammalian cells, and one of them is a method using a viral vector. In this method, a target gene is sent to the target cell by infecting the target cell with a virus in which the target gene is integrated into the genome. Among the viral vectors, adeno-associated virus (hereinafter referred to as “AAV”” is used. The vector (abbreviated as) has already been put into practical use in gene therapy as a viral vector having high safety to humans. However, since the efficiency of AAV infecting mammalian cells varies depending on the cell type and origin, when a cell with low infection efficiency is a target cell, the efficiency of introducing the target gene into the target cell is inferior. Sufficient gene therapy effect is not exhibited.
本発明者らは、これまで視覚障害に対する治療方法についての研究を精力的に行ってきており、その成果として、ＡＡＶベクターを用いた遺伝子治療において、標的細胞である虹彩色素上皮細胞に発現する上皮成長因子受容体（ｅｐｉｄｅｒｍａｌ ｇｒｏｗｔｈ ｆａｃｔｏｒ ｒｅｃｅｐｔｏｒ：以下「ＥＧＦＲ」と略称する）のチロシンキナーゼ活性を阻害することで、目的遺伝子である脳由来神経栄養因子遺伝子の導入効率が向上することを、ＥＧＦＲのチロシンキナーゼ活性を阻害する低分子有機化合物であるチルホスチン（ｔｙｒｐｈｏｓｔｉｎ）を用いて確認している（非特許文献１）。しかしながら、チルホスチンは、低濃度（例えばインビトロの実験において１０μＭ）で細胞毒性を示すことが知られている。また、抗がん剤として用いられるヒドロキシ尿素も、ＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に外来遺伝子の導入効率を向上させる作用を有することが知られているが、その作用は極めて弱い。 The present inventors have been energetically conducting research on treatment methods for visual impairment, and as a result, epidermal growth factor expressed in iris pigment epidermal cells, which are target cells, in gene therapy using AAV vector. By inhibiting the tyrosine kinase activity of the growth factor receptor (epidermal growth factor receptor: hereinafter abbreviated as "EGFR"), the efficiency of introduction of the brain-derived neurotrophic factor gene, which is the target gene, is improved. It has been confirmed by using tyrphostin, which is a low molecular weight organic compound that inhibits kinase activity (Non-Patent Document 1). However, tyrphostin is known to be cytotoxic at low concentrations (eg 10 μM in in vitro experiments). Hydroxyurea, which is used as an anticancer agent, is also known to have an effect of improving the efficiency of introducing a foreign gene when introducing a foreign gene into mammalian cells using an AAV vector. Its action is extremely weak.
そこで本発明は、ＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に用いる、外来遺伝子の導入効率の新規な向上剤を提供することを目的とする。 Therefore, an object of the present invention is to provide a novel agent for improving the efficiency of introducing a foreign gene, which is used when introducing a foreign gene into a mammalian cell using an AAV vector.
本発明者らは上記の点に鑑みて鋭意検討を行った結果、膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドが、ＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際、外来遺伝子の導入効率の向上剤の有効成分として有用であることを見出した。 As a result of diligent studies in view of the above points, the present inventors have obtained a binding peptide of a peptide having membrane permeability and a peptide that inhibits the tyrosine kinase activity of EGFR against mammalian cells using an AAV vector. When introducing a foreign gene, it was found to be useful as an active ingredient of an agent for improving the efficiency of introducing a foreign gene.
上記の点に鑑みてなされた本発明のＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に用いる、外来遺伝子の導入効率の向上剤は、請求項１記載の通り、ＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドのＣ末端に膜透過性を有するペプチドを結合させた結合ペプチドを有効成分とする。
また、請求項２記載の外来遺伝子の導入効率の向上剤は、請求項１記載の外来遺伝子の導入効率の向上剤において、哺乳動物細胞が網膜細胞である。
また、請求項３記載の外来遺伝子の導入効率の向上剤は、請求項１記載の外来遺伝子の導入効率の向上剤において、外来遺伝子が光感受性陽イオン選択的チャネル遺伝子である。
また、本発明の哺乳動物細胞に対する外来遺伝子の導入効率を向上させる方法は、請求項４記載の通り、インビトロにおいてＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際、ＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドのＣ末端に膜透過性を有するペプチドを結合させた結合ペプチドを存在させることによる。
また、本発明は、請求項５記載の通り、ＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドのＣ末端に膜透過性を有するペプチドを結合させた結合ペプチドに関する。
また、本発明のインビトロにおいてＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する方法は、請求項６記載の通り、ＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドのＣ末端に膜透過性を有するペプチドを結合させた結合ペプチドの存在下で行うものである。
As described in claim 1, the agent for improving the efficiency of introducing a foreign gene, which is used when introducing a foreign gene into a mammalian cell using the AAV vector of the present invention made in view of the above points, is EGFR. The active ingredient is a binding peptide in which a peptide having membrane permeability is bound to the C-terminal of the peptide that inhibits tyrosine kinase activity.
Further, in the agent for improving the transfer efficiency of a foreign gene according to claim 2, the mammalian cell is a retinal cell in the agent for improving the transfer efficiency of a foreign gene according to claim 1.
Further, in the agent for improving the transfer efficiency of a foreign gene according to
Further, as described in claim 4, the method for improving the efficiency of introducing a foreign gene into a mammalian cell of the present invention is that when a foreign gene is introduced into a mammalian cell using an AAV vector in vitro, EGFR tyrosine is used. This is due to the presence of a binding peptide to which a peptide having membrane permeability is bound to the C-terminal of the peptide that inhibits kinase activity.
Further, as described in claim 5, the present invention relates to a binding peptide in which a peptide having membrane permeability is bound to the C-terminal of a peptide that inhibits the tyrosine kinase activity of EGFR.
In addition, the method of introducing a foreign gene into a mammalian cell using an AAV vector in vitro of the present invention provides membrane permeability to the C-terminal of a peptide that inhibits the tyrosine kinase activity of EGFR, as described in claim 6. This is performed in the presence of a binding peptide to which the peptide to be possessed is bound.
本発明によれば、ＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に用いる、外来遺伝子の導入効率の向上剤の有効成分として、膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドを提供することができる。 According to the present invention, a peptide having membrane permeability and a tyrosine kinase of EGFR are used as an active component of an agent for improving the efficiency of introducing a foreign gene, which is used when introducing a foreign gene into a mammalian cell using an AAV vector. Binding peptides of peptides that inhibit activity can be provided.
本発明のＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に用いる、外来遺伝子の導入効率の向上剤は、膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドを有効成分とする。 The agent for improving the efficiency of introducing a foreign gene, which is used when introducing a foreign gene into a mammalian cell using the AAV vector of the present invention, is a peptide having membrane permeability and a peptide that inhibits the tyrosine kinase activity of EGFR. The binding peptide is the active ingredient.
本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドにおいて、膜透過性を有するペプチドは、細胞膜を通過して細胞質内へ移行する作用を持つ自体公知のアミノ酸配列を有するもの（Ｃｅｌｌ Ｐｅｎｅｔｒａｔｉｎｇ Ｐｅｐｔｉｄｅ：ＣＰＰ）であってよく、例えば、ＨＩＶ−１ Ｔａｔに由来するＹＧＲＫＫＲＲＱＲＲＲ（配列番号１）、ＦＨＶ ｃｏａｔに由来するＲＲＲＲＮＲＴＲＲＮＲＲＲＶＲ（配列番号２）、ＨＩＶ−１ Ｒｅｖに由来するＴＲＱＡＲＲＮＲＲＲＲＷＲＥＲＱＲ（配列番号３）、ＢＭＶ Ｇａｇに由来するＲＡＱＲＲＡＡＡＲＲＮＲＷＴＡＲ（配列番号４）、ＨＴＬＶ−ＩＩ Ｒｅｘに由来するＴＲＲＱＲＴＲＲＡＲＲＮＲ（配列番号５）などが挙げられる（必要であれば例えば、二木史朗、蛋白質核酸酵素、Ｖｏｌ．４７ Ｎｏ．１１（２００２）１４１５−１４１９を参照のこと）。これらのアミノ酸配列は、膜透過性を有する限りにおいて１〜５個のアミノ酸が欠失、置換または付加したものであってもよい。 Among the binding peptides of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention, the peptide having membrane permeability is a known amino acid sequence having an action of translocating through the cell membrane into the cytoplasm. (Cell Penetrating Peptide: CPP), for example, YGRKKRRQRRR (SEQ ID NO: 1) derived from HIV-1 Tat, RRRRRNRTRRNRRRRVR (SEQ ID NO: 2) derived from FHV coat, and HIV-1 Rev. Examples thereof include TRQARRNRRRRWRERRQR (SEQ ID NO: 3), RAQRRARAARRNRWTAR derived from BMV Gag (SEQ ID NO: 4), TRRQRRTRARRNR derived from HTLV-II Rex (SEQ ID NO: 5), and the like (for example, Shiro Futaki, protein nucleic acid enzyme). , Vol. 47 No. 11 (2002) 1415-1419). These amino acid sequences may be those in which 1 to 5 amino acids have been deleted, substituted or added as long as they have membrane permeability.
本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドにおいて、ＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドは、自体公知のアミノ酸配列を有するものであってよく、例えば、ＥＧＦＲの自己リン酸化部位であるＹ９９２に由来するＤＥＹＬＩ（配列番号６）、Ｙ１０６８に由来するＶＰＥＹＩＮＱ（配列番号７）、Ｙ１１４８に由来するＤＹＱＱＤ（配列番号８）、Ｙ１１７３に由来するＥＮＡＥＹＬＲ（配列番号９）などが挙げられる（必要であれば例えば、Ｍｉｎｅｏ Ａｂｅ，ｅｔ ａｌ．，Ｂｒｉｔｉｓｈ Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｏｌｏｇｙ，２００６；１４７：４０２−４１１を参照のこと）。これらのアミノ酸配列は、ＥＧＦＲのチロシンキナーゼ活性を阻害する限りにおいて１〜５個のアミノ酸が欠失、置換または付加したものであってもよい。 Among the binding peptides of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention, the peptide that inhibits the tyrosine kinase activity of EGFR may have an amino acid sequence known per se, for example. DEYLI (SEQ ID NO: 6) derived from Y992, which is the self-phosphorylating site of EGFR, VPEYINQ (SEQ ID NO: 7) derived from Y1068, DYQQD (SEQ ID NO: 8) derived from Y1148, and ENAEYLR (SEQ ID NO: 9) derived from Y1173. ) Etc. (see, for example, Mineo Abe, et al., British Journal of Pharmacology, 2006; 147: 402-411). These amino acid sequences may be deleted, substituted or added with 1 to 5 amino acids as long as they inhibit the tyrosine kinase activity of EGFR.
本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、膜透過性を有するペプチドのＣ末端にＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドを結合させてもよいし、ＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドのＣ末端に膜透過性を有するペプチドを結合させてもよい。具体例としては、ＨＩＶ−１ Ｔａｔに由来するＹＧＲＫＫＲＲＱＲＲＲのＣ末端にＹ１０６８に由来するＶＰＥＹＩＮＱやＹ１１４８に由来するＤＹＱＱＤを結合させたペプチド、ＦＨＶ ｃｏａｔに由来するＲＲＲＲＮＲＴＲＲＮＲＲＲＶＲのＣ末端にＹ１１７３に由来するＥＮＡＥＹＬＲを結合させたペプチド、Ｙ１０６８に由来するＶＰＥＹＩＮＱのＣ末端にＨＩＶ−１ Ｔａｔに由来するＹＧＲＫＫＲＲＱＲＲＲを結合させたペプチドなどが挙げられる。 The binding peptide of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention may bind a peptide that inhibits tyrosine kinase activity of EGFR to the C-terminal of the peptide having membrane permeability. , A peptide having membrane permeability may be bound to the C-terminal of the peptide that inhibits the tyrosine kinase activity of EGFR. As a specific example, a peptide in which VPEYINQ derived from Y1068 or DYQQD derived from Y1148 is bound to the C-terminal of YGRKKRRQRRRR derived from HIV-1 Tat, and ENAEYLR derived from Y1173 at the C-terminal of RRRRNRTRRNRRRRVR derived from FHV cot. Examples thereof include a bound peptide, a peptide in which YGRKKRRQRRR derived from HIV-1 Tat is bound to the C-terminal of VPEYINQ derived from Y1068.
本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、ペプチド合成機を用いて化学合成することができるが、遺伝子工学的手法によって調製してもよい。 The binding peptide of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention can be chemically synthesized using a peptide synthesizer, but may be prepared by a genetic engineering technique.
なお、本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、ＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際の安定性を保つことなどを目的として、そのＮ末端をアセチル化したりＣ末端をアミド化したりしてもよい。 The binding peptide of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention maintains stability when introducing a foreign gene into a mammalian cell using an AAV vector. The N-terminal may be acetylated or the C-terminal may be amidated for the purpose of.
本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、例えば水溶性の粉末である。従って、インビトロにおいてＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際、細胞の培養液に溶解して例えば１〜２４時間、３７℃でインキュベートした後、ウイルスを細胞に感染させることで、外来遺伝子の導入効率を向上させることができる。また、インビボにおいては、本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドを、外来遺伝子を組み込んだＡＡＶベクターの溶液に溶解してから、体内に投与してウイルスを細胞に感染させることで、外来遺伝子の導入効率を向上させることができる。本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドの、細胞の培養液への溶解量や外来遺伝子を組み込んだＡＡＶベクターの溶液への溶解量は、例えば０．１μＭ〜１０Ｍの範囲になるように適宜設定すればよい。なお、本発明において、哺乳動物細胞は、ヒト、サル、マウス、ラット、ハムスター、モルモット、ウシ 、ブタ、ウマ、ウサギ、ヒツジ、ヤギ、ネコ、イヌなどの各種の部位の細胞であってよい。外来遺伝子は、標的細胞に対して導入されることで、例えば疾患の治療効果を発揮するものなどであってよい。具体的には、哺乳動物細胞としては、哺乳動物の網膜細胞（網膜を構成する神経細胞やグリア細胞や色素上皮細胞など）が挙げられる。外来遺伝子としては、視覚機能に重要な役割を果たす光受容チャネルロドプシンなどの光感受性陽イオン選択的チャネルの遺伝子が挙げられる。ＡＡＶベクターへの光感受性陽イオン選択的チャネル遺伝子の組み込みや、光感受性陽イオン選択的チャネル遺伝子を組み込んだＡＡＶベクターの網膜細胞への導入は、例えばＴｏｍｉｔａ Ｈｉｒｏｓｈｉ，ｅｔ ｓｌ．，Ｍｏｌ Ｔｈｅｒ．，２０１４；２２（８）：１４３４−１４４０に記載の方法に従って行うことができる。本発明者らは、この文献において、光感受性陽イオン選択的チャネル遺伝子を組み込んだＡＡＶベクターを網膜細胞に導入にすることによって視覚機能が回復することを報告したが、本発明における膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、より少量の光感受性陽イオン選択的チャネル遺伝子を組み込んだＡＡＶベクターによる、より効果的な視覚機能の回復に寄与する。 The binding peptide of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention is, for example, a water-soluble powder. Therefore, when introducing a foreign gene into a mammalian cell using an AAV vector in vitro, the cell is infected with the virus after being dissolved in a cell culture solution and incubated at 37 ° C. for, for example, 1 to 24 hours. Therefore, the efficiency of introducing foreign genes can be improved. In vivo, the binding peptide of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR in the present invention is dissolved in a solution of an AAV vector incorporating a foreign gene and then administered into the body. By infecting cells with a virus, the efficiency of introducing foreign genes can be improved. In the present invention, the amount of the peptide binding peptide of the peptide having membrane permeability and the peptide that inhibits the tyrosine kinase activity of EGFR dissolved in the cell culture solution or the amount of the AAV vector incorporating the foreign gene incorporated in the solution is, for example, 0. It may be appropriately set so as to be in the range of 1 μM to 10 M. In the present invention, the mammalian cells may be cells of various sites such as humans, monkeys, mice, rats, hamsters, guinea pigs, cows, pigs, horses, rabbits, sheep, goats, cats, and dogs. The foreign gene may be, for example, one that exerts a therapeutic effect on a disease by being introduced into a target cell. Specifically, examples of mammalian cells include mammalian retinal cells (nerve cells, glial cells, pigment epithelial cells, etc. that constitute the retina). Foreign genes include genes for photosensitive cation-selective channels such as the photoreceptive channel rhodopsin, which plays an important role in visual function. Integration of the photosensitive cation-selective channel gene into the AAV vector and introduction of the AAV vector incorporating the light-sensitive cation-selective channel gene into the retinal cells are described, for example, in Tomita Hiroshi, et sl. , Mol Ther. , 2014; 22 (8): 1434-1440. The present inventors have reported in this document that the visual function is restored by introducing an AAV vector incorporating a light-sensitive cation-selective channel gene into retinal cells, but the membrane permeability in the present invention is described. The binding peptide between the peptide and the peptide that inhibits the tyrosine kinase activity of EGFR contributes to more effective restoration of visual function by the AAV vector incorporating a smaller amount of the photosensitive cation-selective channel gene.
以下、本発明を実施例によって詳細に説明するが、本発明は以下の記載に限定して解釈されるものではない。 Hereinafter, the present invention will be described in detail by way of examples, but the present invention is not construed as being limited to the following description.
実施例１：
カニクイザル由来の繊維芽細胞株であるＣＹＮＯＭ−Ｋ１を９６ウェルプレートにそれぞれ１×１０４個ずつ播種し、１０％ＦＢＳを含むＭＥＭ培地で、１日、３７℃でインキュベートした。１×ＤＰＢＳで２回ｗａｓｈした後、４０ｍＭのヒドロキシ尿素（ＨＵ）（１ｍＭの酪酸ナトリウムを含む）、１０μＭのチルホスチン（Ｔｙｒ）、被験物質としての各種の濃度のＡｃｅｔｙｌ−ＹＧＲＫＫＲＲＱＲＲＲＶＰＥＹＩＮＱ−ＣＯＮＨ２（配列番号１０：Ｓｈｉｍａｄｚｕ社のペプチド合成機ＰＳＳＭ−８を用いた化学合成による水溶性の白色粉末）をそれぞれ加え、５時間、３７℃でインキュベートした。インキュベートを終了した後、２％ＦＢＳを含むＭＥＭ培地で２回ｗａｓｈしてから、市販のＡＡＶとｐｍＣｈｅｒｒｙ−Ｎ１ Ｖｅｃｔｏｒを用いてメーカのマニュアルに従って作製したＡＡＶ−ｐｍＣｈｅｒｒｙ（１×１０１２〜１３ｐａｒｔｉｃｌｅ／ｍＬ）２．５μＬ＋２％ＦＢＳを含むＭＥＭ培地４７．５μＬをウイルス溶液として加え、２時間、３７℃でインキュベートした後、１８％ＦＢＳを含むＭＥＭ培地を５０μＬ加えた。１日後に培地交換を行い、さらに３日間培養した。その後、核染色剤であるＨｏｅｃｈｓｔ３３３４２溶液を５μｇ／ｍＬになるように加え、３０分間、室温でインキュベートし、蛍光顕微鏡で細胞の写真を撮影した。撮影した写真から、ｍＣｈｅｒｒｙ遺伝子の発現効率を、Ｈｏｅｃｈｓｔ３３３４２によって核が青色に染色された全細胞数に対する、ｍＣｈｅｒｒｙによって核が赤色に染色された細胞数の比率として計算した。結果を図１に示す（無処理群をコントロールとする相対値）。図１から明らかなように、被験物質である膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、濃度依存的にｍＣｈｅｒｒｙ遺伝子の導入効率を向上させることで発現効率を向上させ、その作用はチルホスチンに匹敵するものであった。なお、この被験物質は、チルホスチンよりも低毒性であった（例えばインビトロの実験において１ｍＭでも細胞毒性を示さない）。
Example 1:
CYNOM-K1 which is a fibroblast cell line derived from cynomolgus monkey was seeded in 96-well plates in an amount of 1 × 10 4 each, and incubated in MEM medium containing 10% FBS at 37 ° C. for 1 day. After washing twice with 1 × DPBS, 40 mM hydroxyurea (HU) (including 1 mM sodium butyrate), 10 μM tyrphostin (Tyr), various concentrations of Acetyl-YGRKKRRQRRRBPEYINQ-CONH 2 as a test substance (SEQ ID NO: 10: Water-soluble white powder by chemical synthesis using a peptide synthesizer PSSM-8 manufactured by Shimadzu) was added, and the mixture was incubated at 37 ° C. for 5 hours. After completion of the incubation, wash twice in MEM medium containing 2% FBS, and then AAV-pmCherry (1 × 10 12-13 virus /) prepared according to the manufacturer's manual using commercially available AAV and pmCherry-N1 Virus. mL) 47.5 μL of MEM medium containing 2.5 μL + 2% FBS was added as a virus solution, and after incubating at 37 ° C. for 2 hours, 50 μL of MEM medium containing 18% FBS was added. The medium was changed after 1 day, and the cells were cultured for another 3 days. Then, a solution of Hoechst33342, a nuclear stain, was added to 5 μg / mL, incubated for 30 minutes at room temperature, and the cells were photographed with a fluorescence microscope. From the photographs taken, the expression efficiency of the mCherry gene was calculated as the ratio of the number of cells whose nuclei were stained red by mCherry to the total number of cells whose nuclei were stained blue by Hoechst33342. The results are shown in FIG. 1 (relative values with the unprocessed group as the control). As is clear from FIG. 1, the binding peptide of the peptide having membrane permeability, which is the test substance, and the peptide that inhibits the tyrosine kinase activity of EGFR increases the expression efficiency by improving the introduction efficiency of the mCherry gene in a concentration-dependent manner. It was improved and its action was comparable to that of tylhostin. This test substance was less toxic than tyrphostin (for example, even 1 mM did not show cytotoxicity in in vitro experiments).
実施例２：
被験物質としての各種の濃度のＡｃｅｔｙｌ−ＹＧＲＫＫＲＲＱＲＲＲＤＹＱＱＤ−ＣＯＮＨ２（配列番号１１：Ｓｈｉｍａｄｚｕ社のペプチド合成機ＰＳＳＭ−８を用いた化学合成による水溶性の白色粉末）を用いること以外は実施例１と同様にしてそのｍＣｈｅｒｒｙ遺伝子の発現効率に対する作用を評価した。結果を図２に示す。図２から明らかなように、被験物質のｍＣｈｅｒｒｙ遺伝子の発現効率の向上作用はチルホスチンに匹敵するものであった。なお、この被験物質は、チルホスチンよりも低毒性であった（例えばインビトロの実験において１ｍＭでも細胞毒性を示さない）。
Example 2:
Same as Example 1 except that Acetyl-YGRKKRRQRRDYQQD-CONH 2 (SEQ ID NO: 11: water-soluble white powder by chemical synthesis using Shimadzu's peptide synthesizer PSSM-8) is used as a test substance. The effect of the mCherry gene on the expression efficiency was evaluated. The results are shown in FIG. As is clear from FIG. 2, the effect of improving the expression efficiency of the mCherry gene of the test substance was comparable to that of tylhostin. This test substance was less toxic than tyrphostin (for example, even 1 mM did not show cytotoxicity in in vitro experiments).
実施例３：
被験物質としての各種の濃度のＡｃｅｔｙｌ−ＶＰＥＹＩＮＱＹＧＲＫＫＲＲＱＲＲＲ−ＣＯＮＨ２（配列番号１２：Ｓｈｉｍａｄｚｕ社のペプチド合成機ＰＳＳＭ−８を用いた化学合成による水溶性の白色粉末）を用いること以外は実施例１と同様にしてそのｍＣｈｅｒｒｙ遺伝子の発現効率に対する作用を評価したところ、チルホスチンに匹敵するｍＣｈｅｒｒｙ遺伝子の発現効率の向上作用を示した。なお、この被験物質は、チルホスチンよりも低毒性であった（例えばインビトロの実験において１ｍＭでも細胞毒性を示さない）。
Example 3:
Same as Example 1 except that Acetyl-VPEYINQYGRKKRRQRR-CONH 2 (SEQ ID NO: 12: water-soluble white powder by chemical synthesis using the peptide synthesizer PSSM-8 of Shimadzu) is used as a test substance. Then, when the effect on the expression efficiency of the mCherry gene was evaluated, the effect of improving the expression efficiency of the mCherry gene comparable to that of tylhostin was shown. This test substance was less toxic than tyrphostin (for example, even 1 mM did not show cytotoxicity in in vitro experiments).
実施例４：
Ｔｏｍｉｔａ Ｈｉｒｏｓｈｉ，ｅｔ ｓｌ．，Ｍｏｌ Ｔｈｅｒ．，２０１４；２２（８）：１４３４−１４４０に記載の方法に従って以下の実験を行った。緑藻類ボルボックス由来のチャネルロドプシン（ＶＣｈＲ１）を基本構造とした改変型チャネルロドプシン（ｍＶＣｈＲ１）の遺伝子をＡＡＶベクターに組み込み、ｍＶＣｈＲ１遺伝子を組み込んだＡＡＶベクターの溶液（２．５×１０１１ｐａｒｔｉｃｌｅｓ／ｍＬ）５μＬを、３２ゲージハミルトンマイクロシリンジを用いて、失明に至った６ヶ月齢以上の遺伝性網膜変性症（ＲＣＳ，ｒｄｙ／ｒｄｙ）ラット（日本クレア社より購入）の一方の硝子体内に麻酔下で投与した。他方の硝子体内には、ｍＶＣｈＲ１遺伝子を組み込んだＡＡＶベクターと、実施例１に記載の被験物質（Ａｃｅｔｙｌ−ＹＧＲＫＫＲＲＱＲＲＲＶＰＥＹＩＮＱ−ＣＯＮＨ２：Ｔａｔ−Ｙ１０６８）を含む溶液５μＬを投与した（ｍＶＣｈＲ１遺伝子を組み込んだＡＡＶベクターの最終濃度は対側眼と同じで被験物質の最終濃度は４０μＭ）。投与から２ヶ月後に視覚誘発電位を測定した。具体的には、測定の１週間前に脳視覚野に記録用電極の埋め込み手術を行ったラットの眼前にＬＥＤ光源を配置し、１秒間隔で１０ｍｓの光刺激を２００回行い、光刺激に伴って誘発される視覚野の電位変化を記録した。結果を図３に示す。図３から明らかなように、被験物質である膜透過性を有するペプチドとＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドの結合ペプチドは、網膜細胞へのｍＶＣｈＲ１遺伝子の導入効率を向上させることで発現効率を向上させ、視覚誘発電位の振幅を増大させた（遺伝子導入される主たる細胞は神経節細胞である）。
Example 4:
Tomita Hiroshi, et sl. , Mol Ther. , 2014; 22 (8): 1434-1440, the following experiments were performed. A modified channelrhodopsin (mVChR1) gene based on the green algae Volvox-derived channelrhodopsin (VChR1) was incorporated into an AAV vector, and an AAV vector solution (2.5 × 10 11 parts / mL) containing the mVChR1 gene was incorporated into the AAV vector. Was administered under anesthesia into one of the intravitreals of hereditary retinal degeneration (RCS, rdy / rdy) rats (purchased from Claire Japan) 6 months or older who led to blindness using a 32-gauge Hamilton microsyringe. did. In the other intravitreal, 5 μL of a solution containing the AAV vector incorporating the mVChR1 gene and the test substance (Acetyl-YGRKKRRQRRVPEYINQ-CONH 2 : Tat-Y1068) according to Example 1 was administered (AAV incorporating the mVChR1 gene). The final concentration of the vector is the same as that of the contralateral eye, and the final concentration of the test substance is 40 μM). The visual evoked potential was measured 2 months after administration. Specifically, an LED light source was placed in front of the eyes of a rat who underwent an operation to implant a recording electrode in the visual cortex of the brain one week before the measurement, and light stimulation of 10 ms was performed 200 times at 1-second intervals for light stimulation. The accompanying potential changes in the visual cortex were recorded. The results are shown in FIG. As is clear from FIG. 3, the binding peptide of the peptide having membrane permeability, which is the test substance, and the peptide that inhibits the tyrosine kinase activity of EGFR improves the expression efficiency by improving the transfer efficiency of the MVChR1 gene into retinal cells. Improves and increases the amplitude of the visual evoked potential (the main cell into which the gene is introduced is the ganglion cell).
本発明は、ＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に用いる、外来遺伝子の導入効率の新規な向上剤を提供することができる点において、産業上の利用可能性を有する。 The present invention provides industrial applicability in that it can provide a novel agent for improving the efficiency of introducing a foreign gene, which is used when introducing a foreign gene into a mammalian cell using an AAV vector. Have.
上記の点に鑑みてなされた本発明のＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際に用いる、外来遺伝子の導入効率の向上剤は、請求項１記載の通り、膜透過性を有するペプチドのＣ末端にＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドを結合させた結合ペプチドを有効成分とする。
また、請求項２記載の外来遺伝子の導入効率の向上剤は、請求項１記載の外来遺伝子の導入効率の向上剤において、哺乳動物細胞が網膜細胞である。
また、請求項３記載の外来遺伝子の導入効率の向上剤は、請求項１記載の外来遺伝子の導入効率の向上剤において、外来遺伝子が光感受性陽イオン選択的チャネル遺伝子である。
また、本発明の哺乳動物細胞に対する外来遺伝子の導入効率を向上させる方法は、請求項４記載の通り、インビトロにおいてＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する際、膜透過性を有するペプチドのＣ末端にＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドを結合させた結合ペプチドを存在させることによる。
また、本発明は、請求項５記載の通り、膜透過性を有するペプチドのＣ末端にＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドを結合させた結合ペプチドに関する。
また、本発明のインビトロにおいてＡＡＶベクターを用いて哺乳動物細胞に対して外来遺伝子を導入する方法は、請求項６記載の通り、膜透過性を有するペプチドのＣ末端にＥＧＦＲのチロシンキナーゼ活性を阻害するペプチドを結合させた結合ペプチドの存在下で行うものである。
As described in claim 1, the agent for improving the efficiency of introducing a foreign gene, which is used when introducing a foreign gene into a mammalian cell using the AAV vector of the present invention made in view of the above points, is membrane permeation. The active ingredient is a binding peptide in which a peptide that inhibits the tyrosine kinase activity of EGFR is bound to the C-terminal of the peptide having sex .
Further, in the agent for improving the transfer efficiency of a foreign gene according to claim 2, the mammalian cell is a retinal cell in the agent for improving the transfer efficiency of a foreign gene according to claim 1.
Further, in the agent for improving the transfer efficiency of a foreign gene according to
Further, as described in claim 4, the method for improving the efficiency of introducing a foreign gene into a mammalian cell of the present invention is membrane permeability when introducing a foreign gene into a mammalian cell using an AAV vector in vitro. This is due to the presence of a binding peptide in which a peptide that inhibits the tyrosine kinase activity of EGFR is bound to the C-terminal of the peptide having .
Further, as described in claim 5, the present invention relates to a binding peptide in which a peptide that inhibits the tyrosine kinase activity of EGFR is bound to the C-terminal of a peptide having membrane permeability .
In addition, the method of introducing a foreign gene into a mammalian cell using an AAV vector in vitro of the present invention inhibits the tyrosine kinase activity of EGFR at the C-terminal of a peptide having membrane permeability, as described in claim 6. It is carried out in the presence of a binding peptide to which the peptide to be bound is bound.
Claims (6)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015024849 | 2015-02-12 | ||
| JP2015024849 | 2015-02-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574847A Division JP6730705B2 (en) | 2015-02-12 | 2016-02-11 | Agent for improving the efficiency of introducing a foreign gene into mammalian cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020191872A true JP2020191872A (en) | 2020-12-03 |
| JP7142369B2 JP7142369B2 (en) | 2022-09-27 |
Family
ID=56614823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574847A Active JP6730705B2 (en) | 2015-02-12 | 2016-02-11 | Agent for improving the efficiency of introducing a foreign gene into mammalian cells |
| JP2020105583A Active JP7142369B2 (en) | 2015-02-12 | 2020-06-18 | Agent for improving efficiency of introduction of exogenous gene into mammalian cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574847A Active JP6730705B2 (en) | 2015-02-12 | 2016-02-11 | Agent for improving the efficiency of introducing a foreign gene into mammalian cells |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP6730705B2 (en) |
| WO (1) | WO2016129656A1 (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006513985A (en) * | 2002-09-06 | 2006-04-27 | ザ ユニバーシティ オブ サセックス | Fiber shaping peptide capable of interacting with self-assembling peptides |
| US7052692B1 (en) * | 1997-09-02 | 2006-05-30 | Advanced Research & Technology Institute | Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression |
| JP3820105B2 (en) * | 1998-10-23 | 2006-09-13 | キリン−アムジエン・インコーポレーテツド | Dimeric thrombopoietin peptidomimetic that binds to MP1 receptor and has platelet-forming activity |
| JP2011501944A (en) * | 2007-10-19 | 2011-01-20 | コナリス リサーチ インスティチュート アーゲー | Soluble gp130 mutant protein with improved binding activity |
| JP2012510806A (en) * | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | Single-chain antiparallel coiled-coil protein |
| WO2013192550A2 (en) * | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| JP2014523914A (en) * | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Engineered microbial targeting molecules and uses thereof |
| JP2014524737A (en) * | 2011-06-24 | 2014-09-25 | サイチューン | Immune cytokines based on IL-15 and IL-15RαSUSHI domains |
| JP2014529591A (en) * | 2011-08-12 | 2014-11-13 | オメロス コーポレーション | Anti-FZD10 monoclonal antibodies and methods for their use |
| JP2014239682A (en) * | 2006-12-22 | 2014-12-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | New fusion molecule based on novel taa variant |
-
2016
- 2016-02-11 JP JP2016574847A patent/JP6730705B2/en active Active
- 2016-02-11 WO PCT/JP2016/054042 patent/WO2016129656A1/en active Application Filing
-
2020
- 2020-06-18 JP JP2020105583A patent/JP7142369B2/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7052692B1 (en) * | 1997-09-02 | 2006-05-30 | Advanced Research & Technology Institute | Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression |
| JP3820105B2 (en) * | 1998-10-23 | 2006-09-13 | キリン−アムジエン・インコーポレーテツド | Dimeric thrombopoietin peptidomimetic that binds to MP1 receptor and has platelet-forming activity |
| JP2006513985A (en) * | 2002-09-06 | 2006-04-27 | ザ ユニバーシティ オブ サセックス | Fiber shaping peptide capable of interacting with self-assembling peptides |
| JP2014239682A (en) * | 2006-12-22 | 2014-12-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | New fusion molecule based on novel taa variant |
| JP2011501944A (en) * | 2007-10-19 | 2011-01-20 | コナリス リサーチ インスティチュート アーゲー | Soluble gp130 mutant protein with improved binding activity |
| JP2012510806A (en) * | 2008-12-08 | 2012-05-17 | コンプリクス エン ヴェー | Single-chain antiparallel coiled-coil protein |
| JP2014524737A (en) * | 2011-06-24 | 2014-09-25 | サイチューン | Immune cytokines based on IL-15 and IL-15RαSUSHI domains |
| JP2014523914A (en) * | 2011-07-18 | 2014-09-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Engineered microbial targeting molecules and uses thereof |
| JP2014529591A (en) * | 2011-08-12 | 2014-11-13 | オメロス コーポレーション | Anti-FZD10 monoclonal antibodies and methods for their use |
| WO2013192550A2 (en) * | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
Non-Patent Citations (7)
| Title |
|---|
| ABE, MINEO ET AL.: "Inhibition of autophosphorylation of epidermal growth factor receptor by small peptides in vitro", BR. J. PHARMACOL., vol. 147, JPN6021028578, 2006, pages 402 - 411, ISSN: 0004706286 * |
| CHEN, X. ET AL.: "Fusion Protein Linkers: Property, Design and Functionality", ADV. DRUG. DELIV. REV., vol. 65, JPN6022005583, 2013, pages 1357 - 1369, ISSN: 0004706284 * |
| KURODA, YOSHIHIRO ET AL.: "Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated respons", EUR. J. PHARMACOL., vol. 698, JPN6016016249, 2013, pages 87 - 94, ISSN: 0004706280 * |
| MAH, CATHRYN ET AL.: "Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor prote", J. VIROL., vol. 72, JPN6016016251, 1998, pages 9835 - 9843, XP002190083, ISSN: 0004706282 * |
| SUGANO, ERIKO ET AL.: "Establishment of effective methods for transducing genes into iris pigment epithelial cells by using", INVEST. OPHTHALMOL. VIS. SCI., vol. 46, JPN6016016250, 2005, pages 3341 - 3348, ISSN: 0004706281 * |
| TOMITA, HIROSHI ET AL.: "Restoration of the Majority of the Visual Spectrum by Using Modified Volvox Channelrhodopsin-1", MOL. THER., vol. 22, JPN6016016253, 2014, pages 1434 - 1440, ISSN: 0004706285 * |
| ZHONG, LI ET AL.: "Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vecto", J. BIOL. CHEM., vol. 279, JPN6016016252, 2004, pages 12714 - 12723, ISSN: 0004706283 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7142369B2 (en) | 2022-09-27 |
| JP6730705B2 (en) | 2020-07-29 |
| WO2016129656A1 (en) | 2016-08-18 |
| JPWO2016129656A1 (en) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petitjean et al. | Dorsal horn parvalbumin neurons are gate-keepers of touch-evoked pain after nerve injury | |
| US11071790B2 (en) | Method for efficient delivery of therapeutic molecules in vitro and in vivo | |
| US8754048B2 (en) | Light-receiving channel rhodopsin having improved expression efficiency | |
| CN109563153B (en) | anti-RYK antibodies and methods of using the same | |
| US8772233B2 (en) | Method for promoting regeneration of pancreatic beta-cells by administering neurturin | |
| AU2017256910B2 (en) | Optogenetic visual restoration using Chrimson | |
| CN107405414A (en) | Treat the method and composition of cerebral disease | |
| Uezu et al. | Essential role for InSyn1 in dystroglycan complex integrity and cognitive behaviors in mice | |
| CN107847523A (en) | Fissional method for cell after induced mitogenesis | |
| CN109890404A (en) | Visual performance regenerative agent or visual performance reduce prophylactic | |
| US11628206B2 (en) | Method for inhibiting STAT3 activity comprising administering Ssu72 | |
| JP7142369B2 (en) | Agent for improving efficiency of introduction of exogenous gene into mammalian cells | |
| KR20140103002A (en) | Peptide for targeting to mitochondria | |
| DE602004013165T2 (en) | CHIMARICAL VECTOR SYSTEM | |
| WO2023143366A1 (en) | Variant adeno-associated virus and application thereof in disease treatment | |
| US20220226503A1 (en) | Methods for efficient delivery of therapeutic molecules in vitro and in vivo | |
| Spratt | Sodium Channel Dysfunction in Autism Spectrum Disorder | |
| Pavičić | AAV vector based neonatal desensitization for the assessment of cell-replacement therapy for Parkinson’s disease | |
| Zhou et al. | NMDA receptors control cortical axonal projections via EPHRIN-B/EPHB signaling | |
| Hennlein | Plastin 3 rescues defective cell surface translocation and activation of TrkB in mouse models for spinal muscular atrophy | |
| CN117062629A (en) | Methods for reducing degeneration of retinal ganglion cells | |
| CN115335525A (en) | Modified channelrhodopsins | |
| Hillaire | Differential activation of Rac1 accounts for unique neurotrophin-TrkA signals in developing sympathetic neurons | |
| Deheshi | Mitochondrial form and function: an investigation of the mechanism and significance of mitochondrial remodelling in rat cortical astrocytes | |
| Aron | Genetic analysis of dopaminergic neuron survival |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200713 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200713 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220215 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220415 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220906 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7142369 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |